home / stock / gnftf / gnftf news

GNFTF News and Press, Genfit Ord From 11/13/23

Stock Information
Company Name: Genfit Ord
Stock Symbol: GNFTF
Market: OTC
Website: genfit.com
Menu
GNFTF GNFTF Quote GNFTF Short GNFTF News GNFTF Articles GNFTF Message Board
Get GNFTF Alerts

News, Short Squeeze, Breakout and More Instantly...
GNFTF - GENFIT: Results from Ipsen's ELATIVE® pivotal Phase III trial of elafibranor in PBC presented as late breaking data at AASLD congress and published in New England Journal of Medicine

ELATIVE® Phase III trial confirms potential for investigational elafibranor as a novel, first-in-class, dual PPAR α,δ agonist for patients with Primary Biliary Cholangitis. Elafibranor demonstrates significant improvements in biomarkers of disease progression versus pla...
GNFTF - GENFIT Reports Third Quarter 2023 Financial Information

Cash and cash equivalents totaled €93.9 million as of September 30, 2023 Lille (France); Cambridge (Massachusetts, United States); Zurich (Switzerland); November 9, 2023 - GENFIT (Nasdaq and Euronext: GNFT) , a late-stage biopharmaceutical company dedicated to improving the...

GNFTF - GENFIT to Present Update on Scientific and Corporate Progress at The Liver Meeting® 2023

GENFIT to lead 3 key events on ACLF during AASLD: ACLF Day for Investors/Analysts on November 11, 2023 Patient Advocacy Council meeting on November 11, 2023 ACLF Investigator event on November 12, 2023 Detailed interim data from the ELATIVE ® P...

GNFTF - GENFIT Announces Publication in Nature Medicine Confirming the Performance of its NASH Diagnostic Technology  

Lille ( France ) ; Cambridge ( Massachusetts, United States) ; Zurich (Switzerland ); September 2 6 , 202 3 - GENFIT (Nasdaq and Euronext: GNFT) , a late-stage biopharmaceutical company dedicated to improving the lives of patie...
GNFTF - GENFIT Reports First Half-Year 2023 Financial Results and Provides Corporate Update

Cash, cash equivalents and current financial assets totaled €111.8 million as of June 30, 2023 Positive results in the pivotal Phase 3 ELATIVE ® trial in June 2023, paving the way to: a potential submission to the health authorities by Ipsen, and a pote...

GNFTF - CymaBay: Positive Phase 3 Data And Competitive Advantage Established

2023-09-10 06:05:05 ET Summary Positive results achieved in phase 3 RESPONSE study, which used seladelpar for the treatment of patients with primary biliary cholangitis. Positive results of the phase 3 RESPONSE study leads to additional data at an upcoming medical meeting and poss...

GNFTF - GENFIT Announces the Publication of New Data on the Clinical Performance of NIS2+(TM) in Older Patients in Hepatology Communications

Lille ( France ) ; Cambridge ( Massachusetts, United States) ; Zurich (Switzerland ); August 10 , 202 3 - GENFIT (Nasdaq and Euronext: GNFT) , a late-stage biopharmaceutical company dedicated to improving the lives of patients with...
GNFTF - Biggest stock movers today: Aurinia Pharmaceuticals, Accolade, Root and more

2023-06-30 06:07:11 ET Stock index futures rose early Friday following strong U.S. economic data , which grew much more than initially thought in the first quarter. The focus is now on the U.S. personal consumption expenditures price index, or the Fed's favorite inflation ...

GNFTF - Ipsen and GENFIT Announce Positive Results from Phase III ELATIVE® trial of elafibranor in patients with primary biliary cholangitis, a rare cholestatic liver disease

Trial met primary endpoint with a statistically significant higher percentage of patients achieving a clinically meaningful cholestasis response compared to placebo Elafibranor was well tolerated with a safety profile consistent with previous studies Results position elafi...

GNFTF - GENFIT Announces New Data at the European Association for the Study of the Liver (EASL) Congress 2023

Lille ( France ) ; Cambridge ( Massachusetts, United States) ; Zurich (Switzerland ); June 7 , 202 3 - GENFIT (Nasdaq and Euronext: GNFT) , a late-stage biopharmaceutical company dedicated to improving the lives of patients with ra...
Previous 10 Next 10